ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19
Introduction COVID-19, caused by SARS-CoV-2, remains a global pandemic that has affected more than 100 million people worldwide with over 4.8 million deaths as of October 2021. Patients with diabetes have both an increased susceptibility to SARS-CoV-2 infection, enhanced disease severity and increas...
Saved in:
| Main Authors: | John Martin, Kieran Mccafferty, Zoe Hollowood, Donna Lockhart, Jamie Chorlton, Michelle Allan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e049650.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tracheostomy in suspected or confirmed cases of COVID-19
by: Terence Pires de Farias, et al.
Published: (2020-01-01) -
Contagi e memoria storica. 1656-2020: esperienze e percezioni a confronto
by: Giuseppe Foscari
Published: (2020-12-01) -
“This is not science. This is storytelling:” The Poetics of Science in Arcadia
by: Liliane Campos
Published: (2011-12-01) -
Seeing is believing: Unity of Place in Arcadia
by: Susan Blattès
Published: (2011-12-01) -
Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial
by: Torben Hansen, et al.
Published: (2020-01-01)